I do not think it is a secret that most pharma companies are vehemently opposed to the drug pricing provisions in the inflation reduction act. I would be surprised if the lobbying spend across industry is not much more than $9M.
For example, Sanofi individually spent $4.77M lobbying efforts in the US apart from any contributions to trade groups.
PDF warning: https://www.sanofi.com/assets/dotcom/content-app/documents/L...
For perspective, weren't the sales from one drug just in the US alone enough the boost the entire economy of Denmark?
9M is peanuts, it may give you few votes on a matter or two but it doesn't move the big picture a bit.